1
|
Wang HH, Wan NW, Da XY, Mou XQ, Wang ZX, Chen YZ, Liu ZQ, Zheng YG. Enantiocomplementary synthesis of β-adrenergic blocker precursors via biocatalytic nitration of phenyl glycidyl ethers. Bioorg Chem 2023; 138:106640. [PMID: 37320911 DOI: 10.1016/j.bioorg.2023.106640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 05/18/2023] [Accepted: 05/25/2023] [Indexed: 06/17/2023]
Abstract
Enantiopure β-nitroalcohols, as an important class of nitro-containing compounds, are essential building blocks in pharmaceutical and organic chemistry, particularly for the synthesis of β-adrenergic blockers. In this study, we present the successful protein engineering of halohydrin dehalogenase HHDHamb for the enantioselective bio-nitration of various phenyl glycidyl ethers to the corresponding chiral β-nitroalcohols, using the inexpensive, commercially available, and safer nitrite as a nitrating agent. The chiral (R)- and (S)-1-nitro-3-phenoxypropan-2-ols were synthesized by the several enantiocomplementary HHDHamb variants through the whole-cell biotransformation, which showed good catalytic efficiency (up to 43% isolated yields) and high optical purity (up to >99% ee). In addition, we also demonstrated that the bio-nitration method was able to tolerate the substrate at a high concentration of 1000 mM (150 g/L). Furthermore, representative synthesis of two optically active enantiomers of the β-adrenergic blocker metoprolol was successfully achieved by utilizing the corresponding chiral β-nitroalcohols as precursors.
Collapse
Affiliation(s)
- Hui-Hui Wang
- Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China; Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Nan-Wei Wan
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Xin-Yu Da
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Xue-Qing Mou
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Zhu-Xiang Wang
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Yong-Zheng Chen
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Zhi-Qiang Liu
- Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China.
| | - Yu-Guo Zheng
- Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China
| |
Collapse
|
2
|
Wang H, Wan N, Miao R, He C, Chen Y, Liu Z, Zheng Y. Identification and Structure Analysis of an Unusual Halohydrin Dehalogenase for Highly Chemo‐, Regio‐ and Enantioselective Bio‐Nitration of Epoxides. Angew Chem Int Ed Engl 2022; 61:e202205790. [DOI: 10.1002/anie.202205790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Indexed: 11/05/2022]
Affiliation(s)
- Hui‐Hui Wang
- Key Laboratory of Bioorganic Synthesis of Zhejiang Province College of Biotechnology and Bioengineering Zhejiang University of Technology Hangzhou 310014 China
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province Generic Drug Research Center of Guizhou Province Green Pharmaceuticals Engineering Research Center of Guizhou Province School of Pharmacy Zunyi Medical University Zunyi China
| | - Nan‐Wei Wan
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province Generic Drug Research Center of Guizhou Province Green Pharmaceuticals Engineering Research Center of Guizhou Province School of Pharmacy Zunyi Medical University Zunyi China
| | - Run‐Ping Miao
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province Generic Drug Research Center of Guizhou Province Green Pharmaceuticals Engineering Research Center of Guizhou Province School of Pharmacy Zunyi Medical University Zunyi China
| | - Cheng‐Li He
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province Generic Drug Research Center of Guizhou Province Green Pharmaceuticals Engineering Research Center of Guizhou Province School of Pharmacy Zunyi Medical University Zunyi China
| | - Yong‐Zheng Chen
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province Generic Drug Research Center of Guizhou Province Green Pharmaceuticals Engineering Research Center of Guizhou Province School of Pharmacy Zunyi Medical University Zunyi China
| | - Zhi‐Qiang Liu
- Key Laboratory of Bioorganic Synthesis of Zhejiang Province College of Biotechnology and Bioengineering Zhejiang University of Technology Hangzhou 310014 China
| | - Yu‐Guo Zheng
- Key Laboratory of Bioorganic Synthesis of Zhejiang Province College of Biotechnology and Bioengineering Zhejiang University of Technology Hangzhou 310014 China
| |
Collapse
|
3
|
Wang HH, Wan NW, Miao RP, He CL, Chen YZ, Liu ZQ, Zheng YG. Identification and Structure Analysis of an Unusual Halohydrin Dehalogenase for Highly Chemo‐, Regio‐ and Enantioselective Bio‐Nitration of Epoxides. Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202205790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Hui-Hui Wang
- Zunyi Medical University School of Pharmacy CHINA
| | - Nan-Wei Wan
- Zunyi Medical University School of Pharmacy CHINA
| | | | - Cheng-Li He
- Zunyi Medical University School of Pharmacy CHINA
| | | | - Zhi-Qiang Liu
- Zhejiang University of Technology College of Biotechnology and Bioengineering Chaowang Rd. 18# 3100114 Hangzhou CHINA
| | - Yu-Guo Zheng
- Zhejiang University of Technology College of Biotechnology and Bioengineering CHINA
| |
Collapse
|
4
|
Moghimi S, Shafiei M, Foroumadi A. Drug design strategies for the treatment azole-resistant candidiasis. Expert Opin Drug Discov 2022; 17:879-895. [PMID: 35793245 DOI: 10.1080/17460441.2022.2098949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Despite the availability of novel antifungals and therapeutic strategies, the rate of global mortality linked to invasive fungal diseases from fungal infection remains high. Candida albicans account for the most invasive mycosis produced by yeast. Thus, the current arsenal of medicinal chemists is focused on finding new effective agents with lower toxicity and broad-spectrum activity. In this review article, recent efforts to find effective agents against azole-resistant candidiasis, a common fungal infection, are covered. AREAS COVERED Herein, the authors outlined all azole-based compounds, dual target, and new scaffolds (non-azole-based compounds) which were effective against azole-resistant candidiasis. In addition, the mechanism of action and SAR studies were also discussed, if the data were available. EXPERT OPINION The current status of fungal infections and the drawbacks of existing drugs have encouraged scientists to find novel scaffolds based on different methods like virtual screening and fragment-based drug discovery. Machine learning and in-silico methods have found their role in this field and experts are hopeful to find novel scaffolds/compounds by using these methods.
Collapse
Affiliation(s)
- Setareh Moghimi
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Shafiei
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.,Department of Medicinal Chemistry, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran
| | - Alireza Foroumadi
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.,Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
5
|
Vijayan RSK, Kihlberg J, Cross JB, Poongavanam V. Enhancing preclinical drug discovery with artificial intelligence. Drug Discov Today 2021; 27:967-984. [PMID: 34838731 DOI: 10.1016/j.drudis.2021.11.023] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 10/15/2021] [Accepted: 11/19/2021] [Indexed: 12/14/2022]
Abstract
Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.
Collapse
Affiliation(s)
- R S K Vijayan
- Institute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA
| | - Jan Kihlberg
- Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden
| | - Jason B Cross
- Institute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA.
| | | |
Collapse
|